LifeRx.md: Your Partner in Weight Management At LifeRx.md, we are more than just a prescription service
Obtaining insurance coverage is often fraught with difficulties as many insurers reject claims for these drugs, thus exacerbating financial hurdles and potentially preventing patients from getting these transformative therapies
Risks of Microdosing GLP-1 Reduced Effectiveness Because outcomes in clinical studies increase with therapeutic dosing, very low doses may not provide meaningful metabolic benefit
In 2025, the company reported a modest +0.99% YoY revenue growth, but the underlying story is more interesting: Dupixent ($17.8B) remains the clear growth engine, benefiting from expanding indications like COPD and broader patient reach, while the EYLEA franchise ($7.89B) continues to be a core contributor despite facing biosimilar pressure, supported by the transition to EYLEA HD, and Libtayo ($1.45B) is steadily gaining ground in oncology, particularly in lung cancer settings
This combination of effectiveness and safety is accelerating their adoption across both diabetic and non-diabetic obese populations
GLP-1 medications can produce relatively rapid weight loss, which tends to increase the likelihood of excess skin compared to gradual loss through diet and exercise alone